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This review discusses the mechanisms involved in different photosensitive lupus syndromes: acute cutaneous lupus
erythematosus, chronic cutaneous (discoid) lupus erythematosus, subacute cutaneous lupus erythematosus, and neonatal
lupus erythematosus. It is proposed that there are three principal determinants of photosensitivity in lupus: (1) susceptibility
to UVR-induced release of epidermal and dermal cytokines; (2) susceptibility to UVR-induced release or translocation of
sequestered antigens in the epidermis or dermis; and (3) different specific immunologic effector mechanisms, activated by
cytokines and directed against discrete epidermal targets. Several characteristics of photosensitive lupus are discussed in
detail: autoantibody specificities, autoantigen translocation, induction of epidermal intercellular adhesion molecule-a
(ICAM-1), vascular activation, cytokine release and T-cell activation, and clinical phototesting. The role of antibodies to the
extractable nuclear antigens Ro and La and the relationship to subacute cutaneous lupus erythematosus (SCLE) and neonatal
lupus erythematosus is discussed in detail, and a model of SCLE is proposed. J Invest Dermatol 100.58S–68S, 1993
Photosensitivity is one of the major diagnostic criteria of systemic lupus
erythematosus (SLE) [1]. It is a common finding in patients with
advanced, multi-organ disease but is also an important characteristic of
other lupus syndromes associated with much less systemic disease:
subacute cutaneous lupus erythematosus (SCLE), neonatal lupus erythe-
matosus (NLE), and chronic cutaneous lupus erythematosus (CCLE).
Acute cutaneous lupus erythematosus (ACLE) occurs in SLE patients and
presents as the classical malar butterfly eruption often with palmar
erythema, oral erosions, cheilitis, and urticarial or papulosquamous
eruptions on sun exposed skin. It is usually seen in conjunction with
autoantibodies of various specificities [2]. Discoid lupus, or CCLE, is a
very distinctive papulosquamous eruption with follicular plugging,
dyspigmentation, induration and scarring [3,4]. It is frequently not
associated with any defined autoantibodies [4], although the patients
may also be antinuclear antibiody (ANA) positive and a percentage may
have antibodies to single-stranded DNA or Ro [5]. It may be seen in
conjunction with other photosensitive lupus syndromes, and is often
associated with limited systemic disease [4,6]. CCLE may also be found
in photo-protected areas.
SCLE is a diffuse erythematous, non-indurated papulosquamous
eruption with photo-distribution [7–9]. It may be associated with arthritis,
but not usually with significant renal disease. It is commonly associated
with autoantibodies to Ro and La, two extractable nuclear proteins
[8,10–12].
NLE is a fascinating clinical syndrome that presents as isolated
congenital heart block (ICHB), or with a papulosquamous eruption very
similar to SCLE, or with both. It has an almost 100% association with
antibodies to Ro and/or La. Although the ICHB is irreversible, the skin
disease rapidly fades as maternal anti-Ro and La antibodies are
catabolized in the infant, usually before six months of age [13,14].
What are the differences and similarities between these lupus
syndromes? The unifying characteristic of all lupus syndromes and of
animal models of lupus is the production of autoantibodies, usually to
sequestered nuclear or cytoplasmic antigens [13]. Even in CCLE, in
which defined autoantibodies or ANA are frequently not found, tissue
binding of antibodies are found in the dermal-epidermal junction of
discoid lupus skin lesions. The strong association of the photosensitive
papulosquamous eruption of NLE with transplacental transfer of
immunoglobulin G (IgG) of anti-Ro and anti-La specificities, stimulated
interest in how autoantibodies of these particular specificities might
induce tissue damage in several types of photosensitive lupus [10,11].
Ultraviolet light is a trigger for the release or translocation of sequestered
nuclear antigens such as Ro and La [15–17]; it also induces release of
native and denatured DNA [18]. In human disease and in animal models
of LE, such released DNA or nuclear antigens bind to circulating
antibodies or to antibodies in extracellular fluid in tissue, triggering
multi-organ tissue damage. However, many people have significant titers
of anti Ro and La antibodies without ever developing photosensitive skin
disease. It is clear that these antibodies are not the only determinants of
photosensitive lupus. It is also evident that ultraviolet radiation (UVR) has
other important roles in induction on photosensitive lupus beyond
translocation of sequestered antigens.
I hypothesize that there are three principal interrelated determinants
of photosensitivity in lupus erythematosus:
1. Susceptibility to UVR-induced release of epidermal and dermal
cytokines.
2. Susceptibility to UVR-induced release or translocation of seques-
tered antigens in the epidermis or dermis.
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3. Different specific immunologic effector mechanisms, activated by
cytokines, and directed against discrete dermal or epidermal targets.
I further propose that the distinct characteristics of the major
photosensitive lupus syndromes are determined by different specific
immunologic effector mechanisms and differences in sensitivity of
cellular targets to immunologic cytotoxicity. However, the syndromes
might be linked by similar susceptibility to UVR-induced cytokine release
and antigen translocation. A central theme in this hypothesis is that
photosensitive lupus is dependent not just on specific and distinctive
cytotoxic effector mechanisms, but also on genetically determined
responses to UVR that are necessary for ultimate tissue damage. The
remainder of this review will focus on descriptions of several important
characteristics of photosensitivity that have been described in lupus: the
autoantibodies most associated with photosensitivity, the translocation of
sequestered autoantigens by UVR, the induction of epidermal ICAM-1,
vascular activation, cytokine release and T-cell activation, and clinical
photosensitivity. Finally, I will present a model of photosensitive lupus
and discuss how this will direct future investigation.
AUTOANTIBODIES ASSOCIATED WITH
PHOTOSENSITIVITY
In NLE, nearly 100% of the patients have high titers of antibody to Ro and
La [19–21]. In a recent study 96% of the patients were anti-Roþ and
90% were anti-Laþ [21]. It has been observed that the presence of
measurable anti-La antibodies correlated with high titers of anti-Ro [22].
Although the percentages of anti-Ro positivity in NLE sera have
historically been much higher than anti-La positivity, more sensitive
enzyme-linked immunosorbent assay (ELISA) and immunoblotting
techniques have led to the observation that the occurrence of antibodies
to Ro and La are largely concordant [23].
As described in the review by McCauliffe in this issue, the Ro antigen
is a molecular complex containing a 60-kD and a 52-kD protein (and
perhaps 47-kD calreticulin). The Ro complex also contains a number of
RNAs. The La protein is a 48–50-kD protein that also binds to RNAs. In
cells, the Ro and La proteins may be combined with RNA in a large
complex, or may be independently complexed to particular RNAs.
Several investigators have studied the antibodies and tissue antigens
from NLE patients to determine whether there are particular patterns of
antigen or antibody specificities that determine whether fetal heart block
or neonatal skin disease occur. In a study of 20 NLE mothers, Buyon
found an increased incidence of anti-52-kD Ro and anti-48-kD La [21].
In all of these anti-Ro positive sera, the titers of anti-52-kD Ro was higher
than the titer of the 60-kD protein. There is a possibility that these
findings are due to different sensitivities in detecting the two auto-
antibodies, and other investigators feel that it is too early to attribute
specific anti-Ro targets to particular biologic functions. Lee found that
neonatal tissues contained increased amounts of the 50-kD La antigen
compared to adult tissues [24].
Alexander et al recently developed an interesting model to study
increases in myocardial muscle membrane potential induced by NLE sera
[25]. In this system, anti-Ro antibodies appeared to be the active
antibody, and the observed changes in transmembrane potentials were
not increased by adding anti-La. I propose that differences in expression
of ICHB or photosensitive skin disease or both are more likely determined
by temporal factors involving translocation of these antigens at different
organs targets, cytokine effects, and sensitivity of the targets to
immunologic damage at different times of development.
In SCLE the percentage of patients with anti-SSA/Ro and SSB/ La is
somewhat less than in NLE. As recently reviewed by Sontheimer, a strong
association with anti-SSA/Ro is described in most clinical studies [12],
but there continue to be some studies that describe SCLE patients with
low prevalence of anti-SSA/Ro [26]. Differences in clinical criteria for
SCLE and lack of diagnostic immunotesting are certainly a problem in
comparing disparate clinical studies, but there may be genetic differences
in the populations described from different continents that also present
problems.
In a large clinical study of photosensitivity by Rothfield and
colleagues, anti-Ro antibodies were highly associated with photosensi-
tivity in SLE patients, but the presence of anti-Ro in these patients did not
lead to the development of SCLE [27]. Anti-Ro antibodies are also found
in ACLE, but in a low percentage of cases [2]. The occurrence of
asymptomatic mothers of NLE patients indicate that many people with
moderate to high levels of anti-Ro antibody have no clinical disease.
What other factors are necessary to induce active disease?
TRANSLOCATION OF SEQUESTERED ANTIGENS
In 1985 it was demonstrated that antibodies to the extractable nuclear
antigens Ro, RNP, and Sm could be induced to bind to the surface of
cultured human keratinocytes by irradiation with UVR before adding
antibody (Fig 1) [15].We proposed that UVR-induced translocation of the
cytoplasmic and nuclear extractable nuclear antigens to the plasma
membrane of keratinocytes where the antigens could bind extracellular
antibodies. These findings were verified quantitatively using fluores-
cence-activated cell sorter (FACS) analysis [16] and a number of different
models. The antigen translocation was not a by-product of cell death, but
was an energy-dependent process requiring protein synthesis and intact
microfilament function. It was produced by UVB but not UVA, although
synergistic effects of UVB and UVA were not excluded (16). In further
experiments, estradiol was found to also induce or augment translocation
of Ro and La antigens [28]. This might be relevant to the high incidence
Figure 1. UVR induction of the binding of anti-Ro IgG to cultured human
keratinocytes. a shows non-irradiated lceratinocytes incubated with anti-Ro –
positive serum. Nuclei are counterstained with PPD. No antibody binding or
internalization oisseen. b shows irradiated cells incubated with anti-Ro and
fluoresceinated second antibody. Granular IgG deposition of the cells is seen.
Cell junctions are visible in some places.
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of photosensitive skin disease in female NLE patients. Alternatively, high
levels of intrauterine estrogens may induce fetal antigen translocation in
keratinocytes, and perhaps in other sites such as the developing
conduction system.
Detailed ultrastructural evidence of translocation of La to the plasma
membrane by UVR was provided by Bachmann et al [17]. They found
that translocated La was associated with the epidermal growth factor
receptor. The ability to perform similar experiments for Ro has been
hampered by limited availability of monoclonal antibody probes for the
different Ro antigens (see review by McCauliffe and Sontheimer, p. 73).
The binding of antibodies to Ro in intact human epidermis has been
extensively studied by Lee and colleagues in a number of experimental
systems as well as in biopsies from patients with SCLE and NLE [29,30].
Human skin grafted onto nude or SCID mice show preferential deposition
of IgG within the epidermis following injection of antisera containing
anti-Ro, anti-La, anti-RNP, or anti-Sm [29,31]. This IgG binding is
augmented by UVR. An example of this binding of IgG in intact human
skin grafted to a nude mouse is shown in Fig 2. Affinity-purified anti-Ro
binds to the epidermis in this model, producing cell surface, cytoplasmic,
and nuclear patterns of staining. In SCLE patients, a faint granular
deposition is seen in lesional skin, mimicking the patterns seen in the
animal model of antibody binding in the epidermis (Fig 3) [29]. Nieboer
and colleagues described similar IgG deposition as faint dust-like
particles’’ (DLP) in SCLE patients [32]. However, in their patient series
this finding was not so highly associated with anti-Ro.
Other groups have verified that antibodies to Ro, La, RNP, and Sm are
induced to bind to keratinocytes following UVR. Jones demonstrated
similar levels of antibody binding following UVR in a small percentage of
cultured human neonatal keratinocytes [33]. He also found that estradiol
could augment this UVR effect [34]. Most recently, Golan et al have
shown that UVR can induce anti-Ro, anti-La, anti-Sm, and anti-RNP
binding to cultured human keratinocytes from SLE patients, most of
whom had clinical photo-sensitivity [35]. In distinction to all previous
studies in which antibody binding was found in 25% of cells or less, they
were able to induce antibody binding in 50% or greater of cells in a dose-
dependent fashion. Interesting, autologous sera from the SLE patients
sometimes increased the level and percentage of binding. This supports
the possibility that susceptibility to UVR may be a genetic trait in LE
patients, and that autoantibodies or cytokines in patients’ sera might
prime cells for this UVR effect. Another intriguing possibility is that lupus
patients might have enhanced expression of molecules that participate in
Ro/La translocation. Heat shock proteins (hsp) are good candidates for
such function as molecular ‘‘chaperones’’.
The fate of antibody bound to translocated Ro, La, and RNP antigens
is an important question, stimulated by the findings of intracellular
antibody in skin biopsies from SCLE patients, of nuclear antibody binding
in the skin in MCTD and SCLE, and of internalized antibody in the
cytoplasm and nucleus of the antibody binding model using nude SCID
mice. We developed an experimental approach to this to study antibody
binding to keratinocytes in intact epidermal sheets [16]. Subjects’
forearms were irradiated in vivo, and 24h later suction blister roofs
were harvested from sites of radiation. These intact epidermal sheets
were then incubated with SCLE patients’ sera with different antibody
specificities for increasing periods of time. As summarized in Table I
and Table II, IgG from a sera containing anti-Ro and anti-La bound
progressively to the cell membrane, then the cytoplasm, then the nucleus
of keratinocytes in intact epidermal sheets (Fig 4). Similar findings were
found with anti-RNP, only with more rapid movement to the nucleus. In
the same model, anti-DNA positive sera produced only occasional
positive staining in basal cells, damaged by suction blister formation. In
Fig 4b, IgG from anti-Ro and La positive sera are bound as halos to the
surface of many keratinocytes after 2 h. By 4 h more fine granular
cytoplasmic staining is seen (Fig 4c). Finally, nuclear staining is
prominent at 16 h (Fig 4d). Anti-RNP internalization to the nucleus was
seen more rapidly (Fig 5). Similar results can be observed in vitro in
cultured keratinocytes, where anti-RNP antibodies bind to the surface
and are internalized in viable cultured keratinocytes (Fig 6). Our previous
experiments have supported the proposition that internalization of IgG to
Ro, La, RNP, or Sm is not an artifact of sectioning tissue, but occurs in
viable keratinocytes or intact epidermal sheets in culture [29]. With anti-
nRNP antibodies, these findings are germane to the ANA seen in
epidermal keratinocytes in skin biopsies from MCTD patients. Whether
Figure 2. Binding of human IgG in human epidermis grafted onto a nude
mouse, following IV injection of anti-Ro-positive sera into the mouse, a shows
the human epidermis after injection of normal human serum into mouse. No
significant antibody deposition is seen, b shows the epidermis after injecting
anti-Ro þ serum from an SCLE patient. Granular IgG deposition is seen over
the basal cell layer, including antibody internalization and nuclear staining.
Cell surface, cytoplasmic, and nuclear staining is seen higher in the
epidermis. Epidermal nuclei appear red due to PPD counter-staining.
Figure 3. Fine granular IgG is seen in the nucleus and cytoplasm in the
epidermis of this section of skin from an SCLE patient.
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this antibody internalization has functional significance remains to be
determined.
Investigators who have studied translocation of Ro, La, RNP, and Sm
in keratinocytes have been perplexed by the individual variability in this
phenomenon. We have recently described a number of responses in
keratinocytes to UVR and cytokines that also show considerable
individual variability (Middleton MH, Norris DA: Induction of inter-
cellular adhesion molecule-1 expression by tumor necrosis factor-alpha
correlates with induction by ultraviolet radiation in cultured human
keratinocytes (manuscript in preparation).). Recent studies by Golan et al
have shown that one can more predictably induce translocation of these
extractable nuclear antigens using keratinocytes from SLE patients [35].
Extensive studies in our own laboratories have shown that no single
cytokine alone [interleukin 1 (IL-1), tumor necrosis factor alpha (TNF-a),
gamma interferon (IFN-g), or IL-6) can induce Ro or La antigen
translocation reproducibly in multiple keratinocyte strains.
Venables has shown that similar translocation of La to the cell
membrane can be induced by infection with herpes virus in a selected
cell line [36]. He showed that gamma interferon could induce some La
translocation within the cell, but that virus infection was necessary to
translocate La to the cell membrane. Other investigators have also show
that virus infection can induce this antigen translocation [37,38]. Is La
translocation induced by cytokines and/or stress proteins?
There has been great interest recently in the role of hsp as molecular
chaperonins, binding to and escorting molecules to the nucleus, to
cytoplasmic vacuoles, to the endoplasmic reticulum, and to the plasma
membrane during stress [39]. It is proposed that such chaperon activity
might be extremely important in translocation of sequestered antigens to
the cell surface in the induction of autoimmunity [39]. There is also much
interest in hsp as integral components of the transport of processed
Table I. Antibody Internalization in Intact Epidermis





Bound IgG 2h 4h 16h
Anti-Ro plus Cell surface +++ ++ +
Anti-La Cytoplasmic ++ ++ ++
Nuclear + ++ +++
Anti-RNP Cell Surface ++ + +
Cytoplasmic + + +
Nuclear + ++ ++
aUVR at – 24 h, harvest epidermis at – 1 h, add serum in organ culture at
0 h, harvest for sectioning and indirect immunofluorescence at 2, 4, and
16 h.
Table II. Individual Variability in Cytokine Effects in
Keratinocyte Cultures
1. UVR induction of ICAM-1 expression
2. UVR induction of TNF-a release
3. TNF-a induction of ICAM-1 expression
4. TNF-a induction of icIL-1 and icIL-lra
5. Absolute and relative levels of icIR-lra and icIL-lra
6. IFN-g induction of cell surface ICAM-1
7. UVR induction of Ro, La, Sm, RNP expression
Figure 4. A model for internalization of IgG in the human skin. The subject’s
forearm is irradiated in vivo, and 24 h later suction blisters are harvested from
the site. The intact epidermis is then incubated with anti Ro plus anti-Laþ
serum from an SCLE patient. Immunofluorescence staining for IgG is then
done on sections from the epidermal sheet, a-d are all incubated with the
same serum, a) Unirradiated epidermis incubated with SCLE patient’s serum
for 16 h. No significant IgG deposition is seen. Red nuclear staining is due to
PPD. The stratum corneum is toward the upper pole of the figure, b) UV-
radiated (200 mj/cm2) epidermis incubated with SCLE serum for 2 h. Note the
halos of IgG around distinct epidermal cells, c) Irradiated skin after 4 h
incubation with SCLE serum. More cytoplasmic and nuclear staining are
noted, d) Irradiated skin after 16 h incubation with antiserum. There is more
nuclear staining in the upper epidermis, and new granular staining in the
lower epidermis.
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antigens and major histo-compatibility complex (MHC) molecules to the
plasma membrane [40]. It is also proposed that hsp themselves might be
targets of autoimmune reactivity. In human keratinocytes, hsp can be
induced by ultraviolet radiation as well as by heat [41–43]. We have
begun to test the hypothesis that hsp plus certain UVR-inducible
cytokines can induce Ro and La translocation, mimicking the UVR
effect. Figure 7 shows the results of one experiment in which heat shock
and TNF-a induced binding of IgG from anti-Ro- and anti-La-positive sera
to the surface of keratinocyte cultured from a TNF-a responsive adult
male donor. The pattern of diffuse cell surface staining is similar to that
seen in UVR-treated keratinocytes. Furu-kawa et al have shown that a
leukotriene that induces hsp can also induce Ro antigen translocation
(personal communication). We are testing whether different combina-
tions of heat shock, TNF-a, IL-1, and IFN-g are able to induce Ro/La
antigen translocation in cells taken from different donors and from SCLE
patients. Individual differences in UVR release of cytokines, or in
response to cytokines, may be an important determinant of which
individuals develop photosensitive LE. A number of investigators have
shown that hsp induction is greater in peripheral blood mononuclear
cells from lupus patients compared to normal subjects or in lymphoid
cells from infiltrates in lupus nephritis [44,45]. Lupus patients also make
autoantibodies to hsp [46,47]. It is essential to determine whether this is a
genetic or acquired characteristic of cells from lupus patients.
If keratinocytes from these patients also show enhanced induction of
hsp, this might be a factor in enhanced Ro and La translocation in lupus
keratinocytes following UVR, as described by Golan et al [35].
The extensive studies on antibody binding to translocated Ro, La,
RNP, and Sm antigens have shown that IgG autoantibodies of these
specificities can bind to the surface of keratinocytes and be internalized.
This binding is enhanced by UVR and estradiol, two triggers of lupus
erythematosus. The functional significance of keratinocyte bound or
internalized IgG has not yet been established.
INDUCTION OF ICAM-1 EXPRESSION ON HUMAN
KERATINOCYTES
The induction of ICAM-1 expression on the surface of human
keratinocytes by UVR and cytokines is one biologic system that clearly
demonstrates significant individual variability. ICAM-1 is the major
ligand for LFA-1, an adhesion molecule found on all leukocytes [48].
Both molecules are inducible by a number of cytokines and the affinity of
LFA-1 for ICAM-1 can be increased by triggering numerous leukocyte
cell surface receptors [49,50]. The interaction of leukocyte function-
associated antigen 1 (LFA-1) on leukocytes with ICAM-1 on other
leukocytes, on endothelial cells, and on parenchymal cells is a major
function step in inducing the cellular attachments necessary for specific
antigen recognition, leukocyte migration into tissue, and immunologic
cytotoxicity [51]. This ligand/receptor pair is essential in many contact-
dependent interactions between leukocytes and between leukocytes and
parenchymal cells [52–54]. This pair is important in directing leukocytes
into tissue and in initiating and strengthening leukocyte attachment to a
Figure 5. Similar protocol to that used in Fig 4, except that anti-UlRNP serum
is used. Predominant cytoplasmic and nuclear staining is evident even by 4 h
with this antiserum.
Figure 6. Cultured keratinocytes stimulated with UVR and incubated with
anti-m1RNP for 8 h. Here discrete linear cell surface IgG deposition is seen as
well as nuclear staining in these cells. The cells were still viable. Active
internalization and nuclear binding of anti-RNP can been seen both in vitro
and in vivo in human keratinocytes.
Figure 7. Fine granular IgG deposition from an SCLE serum containing anti-
Ro and anti-La is seen on these keratinocytes treated with heat shock plus
TNF-a. The patient is a high TNF-a responder.
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potential parenchymal targets, facilitating specific recognition, and
subsequent cytotoxicity [51,55]. Keratinocytes and melanocytes express
very low constituitive levels of cell surface ICAM-1 [56,57]. Therefore,
the resting epidermis is resistant to leukocyte interactions with leukocytes
by virtue of a lack of expression of ICAM-1. In SCLE, expression of cell
surface ICAM-1 is elevated throughout the epidermis, but is often
enhanced in basal keratinocytes (Fig 8). This diffuse pattern is different
from the pattern of ICAM-1 expression in other diseases with junctional
inflammatory infiltrates such as lichen planus and erythema multiforme
(Bennion SD, David-Bajar KM, Norris DA: Different patterns of
keratinocyte expression of intercellular adhesion molecule-1 in three
diseases producing keratinocyte lysis: subacute cutaneous lupus erythe-
matosus, lichen planus and erythema multiforme (manuscript in
preparation).
Figure 9 shows factors that control induction of ICAM-1 expression in
human keratinocytes. TNF-a, TNF-b, IL-1a, and IL-1b can all induce
ICAM-1 expression in a number of cell types through activation of their
specific receptors [52,58]. However, in cultured human neonatal and
adult keratinocytes, only IFN-g, TNF-a, and TNF-b, but not IL-1, can
induce cell surface ICAM-1 expression [52,59,60]. UVR is also a potent
modulator of ICAM-1 expression [59,60]. In the first 24 h following UVR,
ICAM-1 induction by gamma interferon is inhibited. After 24 h, UVR
induces cell surface ICAM-1 expression and enhances interferon-
induced expression [60]. Both TNF-a and IL-1 have been implicated as
the mediators of this UVR induction of ICAM-1, but definitive proof of the
role of each cytokine in keratinocyte cell lines versus freshly isolated
cells is not yet available.
IL-1-dependent receptor activation is inhibited by the specific
receptor antagonist IL-lra. Human keratinocytes contain large amounts
of intracellular IL-la and also IL-1b, although they do not make proteases
necessary to activate the latter [61]. Human keratinocytes synthesize
large amounts of IL-lra, which is present as an intracellular protein in a
10-25-times excess over cellular IL-la [62]. In our hands, human
keratinocytes and keratinocyte cell lines with high levels of IL-lra do
not show induction of ICAM-1 expression by exogenous IL-la. In a
keratinocyte cell line with low levels of intracellular IL-lra (KB cells),
exogenous IL-1 will induce increases in ICAM-1 expression (Middleton
MH, Kutsch CA, Arend WP, Bigler CA, Norris DA: Determinants of IL-1
induction of intercellular adhesion molecule-1 expression in cultured
human keratinocytes and transformed epithelial cell lines (manuscript in
preparation).
TNF-a and TNF-b act through the types A (75-kD) and B (55-kD)
receptors to stimulate various cellular functions [63]. In human
keratinocytes, TNF acts through a 55-kD receptor [64]. TNF activation
can also be blocked by inhibitors that are proteolytic fragments of the
TNF-R [65,66]. These inhibitors are present locally and systemically. No
inhibitors of gamma interferon-induced ICAM-1 expression have been
found.
Receptor activation by these cytokines leads to second messengers
that induce transcription of the ICAM-1 gene [67,68]. Synthesis is largely
controlled at the transcriptional level, leading to specific mRNA, protein,
glycosylated protein, and rapid cell surface transport and expression.
Transcription is regulated by an upstream promoter region that contains
an inhibitor of constituitive ICAM-1 expression and also contains IFN-g-
and TNF-a-responsive elements [67,68]. Such promoter regions respon-
sive to IL-1 have not been demonstrated in human keratinocytes. TNF-a
and IFN-g synergistically enhance transcription.
By comparing responses of keratinocyte strains obtained from
different individuals, we have demonstrated considerable heterogeneity
in ICAM-1 expression induced by different cytokines and UVR
(Middleton MH, Norris DA: Induction of intercellular adhesion
molecule-1 expression by tumor necrosis factor-alpha correlates with
induction by ultraviolet radiation in cultured human keratinocytes
(manuscript in preparation).). In studying over 50 different keratinocyte
strains, we have found that the ICAM-1 responses to TNF-a and IFN-g are
not linked. Keratinocytes with high ICAM-1 expression following TNF-a
Figure 8. Immunoperoxidase stain of ICAM-1 in a biopsy from an SCLE
lesion. Cell surface ICAM-1 is seen throughout the epidermis, with some
accentuation in the basal zone. Diffuse intracellular and cell surface ICAM-1
was commonly seen in SCLE biopsies.
Figure 9. Control of ICAM-1 expression in keratinocytes. Three cytokines and
their receptors can induce ICAM-1 synthesis: IL-1, TNF, and IFN-g. There are
two types of IL-1 R, activated by IL-la and IL-lb and inhibited by the IL-lra
receptor antagonist. There are two types of TNF receptors, A and B, activated
by TNF-a and TNF-b. The type B 55-kD receptor is found on keratinocytes
[64]. A group of inhibitors compete with the cell bound receptor for binding
of the TNF agonists; these TNF-INH are proteolytic fragments of the receptor
[96]. There is only one IFN-y receptor and no specific inhibitor. Transcription
is the rate-limiting step in ICAM-1 synthesis. Control of transcription is the
major point of intracellular control of ICAM-1 synthesis.
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may have no response to IFN-g; the converse is also true. There is,
however, a strong association between ICAM-1 induction by TNF-a and
ICAM-1 induction by UVR: keratinocyte strains that show high responses
to UVR show high responses to TNF-a. In addition, UVR induces TNF-a
release by human keratinocytes, and the level of release also shows
considerable individual heterogeneity. Krutmann et al have proposed
that IL-1 might also be involved in UVR induction of ICAM-1 expression,
by illustrating that anti-ILa can block UVR induction of ICAM-1 in the KB
cell line. However, we have been unable to induce ICAM-1 expression
by IL-1 in neonatal and adult keratinocytes (Middleton MH, Kutsch CA,
Arend WP, Bigler CA, Norris DA: Determinants of IL-1 induction of
intercellular adhesion molecule-1 expression in cultured human kerati-
nocytes and transformed epithelial cell lines (manuscript in prepara-
tion).), even in cells modulated to upregulate IL-1R expression. The
ICAM-1 expression induced by IL-1 in basal keratinocytes following
intradermal injections in human skin by Groves et al [69] cannot be
repeated in cell culture of pure keratinocytes (even in cells with basal cell
pheno-type), and is likely due to secondary release of other cytokines
such as TNF-a.
TNF-a in very low doses ‘‘primes’’ keratinocytes for subsequent
response to TNF-a at suboptimal doses, enhancing induction of ICAM-1
expression. We have also been unable to demonstrate synergy between
IL-1 and TNF-a in inducing expression of keratinocyte ICAM-1.
However, TNF-a and IFN-y act synergistically in upregulating ICAM-1
expression [70]. Both IFN-g and TNF-a also show increased induction of
ICAM-1 expression in less differentiated keratinocytes (Middleton MH,
Norris DA: Induction of intercellular adhesion molecule-1 expression by
tumor necrosis factor-alpha correlates with induction by ultraviolet
radiation in cultured human keratinocytes (manuscript in preparation).).
Thus, the basal zone of the epidermis is clearly a region of maximal
ICAM-1 expression in epidermis exposed to IFN-g and TNF-a, by virtue of
enhanced response of basal cells to these cytokines, and by virtue of the
proximity of IFN-g production by dermal lymphocytes. IL-1 injected into
the dermis also preferentially induced basal cell ICAM-1 expression [69],
most likely through TNF-a release from endothelial and mast cells.
Heterogeneity in cytokine or UVR induction of ICAM-1 expression in
the epidermis is likely to be an important determinant of epidermal
damage in photosensitive lupus. Either TNF-a released by UVR or IFN-g
released by infiltrating CD4þ lymphocytes might enhance ICAM-1
expression in the epidermis. Individual differences in susceptibility to
UVR, possibly through differences in TNF-a release and response, may
determine which LE patients develop photosensitive skin disease. There
is not yet experimental evidence that validates this hypothesis.
Individual differences in TNF-a responses have been suggested as
determinants of a number of important biologic functions. Streilein has
proposed that UVR induced immunosuppression is related to TNF-a-
dependent effects on Langerhans cells density and function, and perhaps
on other local and systemic effects of TNF-a release [71–73]. Mouse
strains resistant to UVR effects also contain polymorphisms in the TNF-a
gene that correlate with low TNF-a release. Streilein has also found that
UVR induction of skin cancer may also correlate with the ability to
induce UVR immunosuppression. In a series of skin cancer patients, he
found that all patients were susceptible to UVR inhibition of contact
hypersensitivity [74], a form of UVR immunosuppression dependent on
high TNF-a response. However, this UVR immunosuppression was found
in both Black and Caucasian subjects in a phototesting trial [74], and
Blacks are certainly resistant to UVR-induced carcinogenesis. Although
TNF-a-dependent effects may be important in induction of UVR
immunosuppression and carcinogenesis, other factors are also likely to
be necessary [75].
There is also strong precedent for TNF-a as a functional mediator of
tissue damage in lupus erythematosus. In animal models of lupus with
severe nephritis, low levels of TNF-a are endogenously produced, and
severe renal disease can be blocked by administering exogenous TNF-a
[76,77]. In another study, particular TNF-a polymorphisms were strongly
associated with a number of autoimmune diseases: rheumatoid arthritis,
juvenile rheumatoid arthritis, and SLE [78]. In some studies, leukocytes
from lupus patients show diminished TNF-a release following stimulation
[79]; in some studies local TNF-a may be directly associated with tissue
damage [80]. In human lupus, severe renal disease is inversely correlated
with TNF-a response [81]. On the other hand, there are other potentially
important variables associated with severe renal disease: the HLA DR2
genotype is associated with severe renal disease, and the DR3 and DR4
genotype are associated with limited renal disease [81]. However, in
humans the TNF locus is located adjacent to the class II MHC region.
Further study is necessary to determine if photosensitive lupus patients
are high TNF-a responders. Because these patients also do not usually
develop severe renal disease, it is essential to examine whether this
‘‘protection’’ is linked to their TNF-a responder status, or to other factors.
Is TNF responder status a critical factor in determining whether patients
develop severe renal disease or whether they develop limited photo-
sensitivity?
BLOOD VESSEL EFFECTS
Leukocyte migration into tissue requires several factors: step-wise
expression of adhesion molecules on leukocytes and endothelial cells,
and gradients of chemotactic factors to direct leukocyte populations into
the dermis and toward the epidermal, dermal, or adnexal sources of
attractants. Endothelial cell adhesion molecules fall into several groups:
integrins, immunoglobulin family, and LEC-CAMs (see review in this
volume by Swerlick and Lawley). Figure 10 shows the leukocyte/
endothelial adhesion pairs and the cytokines that activate them. As
summarized by Swerlick and Lawley, early induction of E-selectin and
P-selectin on endothelial cells induces attachment of T cells including
memory T cells and skin-homing T cells to skin endothelial cells. Increase
in levels of endothelial vascular cell adhesion molecule 1 (VCAM-1)
enhances binding of VLA-4þ T cells; increase in ICAM-1 on endothelial
cells further enhance binding of LFA-1 positive lymphocytes. These
tightly bound T cells are then positioned to respond to chemotactic
factors in the skin.
Ultraviolet light selectively increases E-selectin, but not VCAM-1, in
dermal endothelial cells [82]. Interestingly, VCAM-1 is not induced by
IL-1 on human dermal microvascular endothelial cells (HDMEC) cultured
from dermal capillaries, but is induced in human umbilical vein
endothelial cells (HUVEC) [83]. It appears that endothelial cells at
different sites demonstrate different patterns of responses to cytokines.
From these data, it appears that UVR may act as a generalized stimulus to
promote early endothelial changes that might lead to migration of
memory and activated T cells into the skin.
Figure 10. Leukocyte/endothelial cell interactions and the adhesion molecule
pairs that control them. Receptor/ligand interactions of Lec-Cam/car-
bohydrates and integrin/immunoglobulin superfamily control leukocyte-
endothelial action. Expression of these adhesion structures are induced by
different cytokines, as indicated.
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Sontheimer developed a model of UVR-induced blood flow in guinea
pig skin, and studied the effects of injection of sera from patients with
SCLE on this model [84]. He found that sera from SCLE patients enhanced
UVR-induced blood flow in this model. Sera containing anti-Ro induced
the greatest increases in blood flow. We can infer from these findings that
anti-Ro antisera may induce blood vessel dilation either directly or
through release of cytokines or inflammatory mediators.
CYTOKINES AND T-CELL ACTIVATION
UVR induces the release of the important primary cytokines IL-1 and
TNF-Q from keratinocytes [85,86], and also induces the release of IL-6
[87]. Other cytokines such as granulocyte/macrophage colony-stimulat-
ing factor and IL-8 are secondarily induced by IL-1 released by UVR [88].
These cytokines and other inflammatory mediators are likely to produce
profound local and systemic inflammation. There is little information on
the local release of inhibitors of these cytokines such as IL-lra or TNF
inhibitor (TNF-INH) by UVR or in photosensitive lupus. Systemic
elevation in TNF has been described in SLE [89].
Alterations in peripheral blood leukocyte numbers and function have
been extensively described in SLE (see review by Cohen, p. 69S).
However, there is little meaningful information on the state of activation
of leukocytes in limited cutaneous photosensitive lupus.
The cellular infiltrates of SCLE and DLE contain macrophages, and
CD4þ and CD8þ lymphocytes [90]. Keratinocytes are MHC class 11þ
and leukocytes within the dermis show some signs of activation such as
class II expression [90].
CLINICAL PHOTOTESTING
For many years it was believed that photosensitive lupus lesions were
induced by UVB alone and that lupus patients developed prolonged
erythema following UVR. Kind and his colleagues have developed a
phototesting technique that reproducibly induces cutaneous lesions in
SCLE patients [91]. In their studies, 53% of the patients reacted to a
combination of UVA plus UVB, 33% reacted to UVB alone, and 14%
reacted to UVA alone. The apparent necessity for UVA in the induction
of SCLE lesions in the majority of patients raises important questions.
Does UVA induce distinct cytokine patterns or adhesion molecules? Is
UVA necessary because it penetrates better into the dermis, inducing
mast cell and endothelial cell activation and cytokine release?
As summarized in a paper in this issue (p. 53S), Kind also questions
the role of anti-Ro antibodies in the positive phototesting results. In his
group of SCLE patients, positive phototesting results did not depend on
the presence of anti-Ro. In these patients, however, anti-Ro was highly
correlated with epidermal changes such as hydropic changes of basal
cells. In lupus tumidus (LET), a form of photosensitive lupus with little
epidermal changes, anti-Ro antibodies were not present. In photosensi-
tive CCLE, anti-Ro was not present. However, in photosensitive SLE, anti-
Ro positivity was associated with positive phototesting.
Kind0s findings clearly demonstrate that antibodies to SSA/Ro are not
necessary for photosensitivity in CCLE and LET. In SCLE, the findings are
not conclusive. In this photosensitivity model, SCLE lesions were very
difficult to induce, required multiple sequential doses of light, and could
be induced only on the upper back. Systemic cytokine release and
T-lymphocyte activation that would occur in generalized UV exposure
were probably not produced. In many patients, only dermal changes
were seen. These studies dramatically enhance our appreciation for the
role of UVA and the potential for mast cell or vascular activation in SCLE,
and also support the contention that anti-Ro antibodies are involved in
epidermal damage in SCLE. They also indicate that anti-Ro is associated
with positive phototesting results in SLE, as previously demonstrated by
Rothfield [27], and that other factors are involved in photosensitivity in
LET, CCLE, and also SCLE. LET and CCLE are largely ANA negative, and
one must question whether antibodies are at all involved in these lupus
syndromes. Perhaps distinct UVR-induced cytokine patterns and auto-
reactive T cells are more likely determinants of disease activity in these
syndromes. In LET and the anti-Ro negative SCLE patients, it is also
problematic to exclude other photosensitive disorders such as PMLE.
Lack of ironclad clinical and histologic diagnostic criteria or distinctive
laboratory findings make the diagnosis of SCLE less than sure in many
instances, and have lead to confusion regarding the diagnosis in many
clinical studies [3], Attempts to codify diagnosis and provide diagnostic
laboratory testing in SCLE are quite necessary [3].
CYTOTOXICITY IN PHOTOSENSITIVE LE
Discrete cytotoxicity of basal keratinocytes is a unifying finding in most
forms of photosensitive LE: SCLE, NLE, ACLE, and CCLE [11]. We have
proposed that antibodies to Ro and/or La might induce keratinocytelysis
by antibody-dependent cellular cytotoxicity mediated by a number of
different mononuclear effector cells present in lupus infiltrates. This
hypothesis is supported by a number of different findings. There is
extensive demonstration that anti-Ro and anti-La antibodies can bind to
the surface of epidermal keratinocytes [15,16,28,31], where they would
be able to induce immunologic effector mechanisms [11,92]. This
antibody binding is preceded by antigen translocation to the plasma
membrane, and this is induced by factors such as UVR and estrogen that
trigger lupus [15,16,28,33–35]. Anti-Ro and -La antibodies are temporally
related to cutaneous disease activity in NLE [13]. Anti-Ro antibodies are
associated with epidermal damage in photo-induced SCLE lesions (see
paper in this issue by Kind). Anti-Ro antibodies from SCLE patients induce
ADCC of cellular targets coated with Ro antigen [92]. The cellular
infiltrates in SCLE contain mononuclear effectors capable of inducing
ADCC [90], although demonstration of active FcR has not been shown.
As of yet, it has not been conclusively shown that anti-Ro and anti-La
antibodies are able to induce ADCC of keratinocyte targets following
UVR-induced translocation of the Ro and La antigens. Alternative
mechanisms are also possible. Complement may also cause keratinocyte
gd damage in photosensitive lupus, although viable keratinocytes are
able to repair complement induced membrane pores [11,93].
In CCLE, autoantibody induction of keratinocyte damage is less likely.
Volc-Platzer proposes that g-d T cells may be the effectors of keratinocyte
lysis in CCLE, perhaps by recognizing UVR-translo-cated hsp in
keratinocytes (see paper by Volc-Platzer et al, p. 84S).
Direct endothelial cell damage by autoantibodies (Ro, La, and/or
others)is also an important possibility that requires further study. Immune
complex-induced platelet aggregation can be an important initiator of
endothelial and leukocyte adhesion molecules, and may be the trigger to
induce activated T-cell migration into the skin, especially in ACLE.
It is likely that leukocytes that are potent cytotoxic effectors in
photosensitive LE must be activated to express integrin receptors and
other adhesion structures that determine their attachment to skin
endothelial cells and migration into the dermis, and must be activated
to express high-affinity LFA-1 to maximize attachment to ICAM-1þ
keratinocyte targets. Testing of leukocytes from LE patients for adhesion
to primed endothelium should be done to determine whether activated
T lymphocytes are available to induce tissue damage in different
photosensitive lupus syndromes. The status of local and systemic
cytokine release in these patients also needed to be quantitated.
PROPOSED MODEL FOR SCLE
Figure 11 illustrates a proposed model that incorporates all of the diverse
factors involved in the induction of SCLE lesions. There are four proposed
phases involved in lesion production, but they would not necessarily
proceed sequentially. In stage I both UVA and UVB release epidermal
and dermal cytokines and inflammatory mediators. In stage II those
cytokines locally induce changes in the dermis and epidermis, and
systemically activate leukocytes, leading to stage III antibody binding,
leukocyte immigration, and leukocyte attachment to the epidermis. In
stage IV keratinocyte lysis by ADCC or by cytotoxic T lymphocytes
occurs, further releasing epidermal cyto-kines. Local T-cell activation,
endothelial activation, and other factors may be involved in the
persistence and extension of lesions.
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In this model, the development of clinical skin disease would depend
on the presence of all of the following factors:
1. Susceptibility to UVR leading to appropriate cytokine patterns, to
induction of adhesion molecule expression, and to translocation of
sequestered nuclear antigens and hsp.
2. Appropriate autoantibody specificities present in high titer: anti-Ro
and anti-La in SCLE and NLE. These antibodies would be present by
transplacental transfer or by virtue of genotype that defines anti-Ro
production (see paper by Provost et al, p. 14S).
3. Activated lymphocytes that arise as autoreactive T cells dependent
on the lupus genotype, or induced by UVR-triggered cyto-kines.
Similar models could be proposed for CCLE, ACLE, and LET with
different specific effectors of tissue damage (antibody, immune
complexes, CTL, g-d T cells) but with similar genetic susceptibility to
UVR-induced cytokine release and response.
In SLE there are also similar questions regarding different patterns of
disease in different individuals. Certain autoantibodies are associated
with particular patterns of disease, such as the association of antibodies
to native or double-stranded DNA with nephritis. But there are other
variables that might affect patterns of disease. Patients with the DR3 or
DR4 genotypes often have limited renal disease, and are also high TNF
responders [81]. Addition of TNF to animal models decreases nephritis
without any effect on autoantibodies [77,94,95]. Tissue or peripheral
blood from SLE patients have elevated levels of hsp [44,45]. In SLE, as in
photosensitive cutaneous lupus, individual differences in immunologic
mediators may greatly modify patterns of disease.
The purpose of this review is to identify the distinct immunologic and
biologic functions that must be involved in inducing the clinical lesions
of photosensitive lupus. Molecular immunology has unlocked the secrets
of many of the molecules that direct and control the immune response.
Study of the dynamic induction of these molecules in the skin during the
development of photosensitive LE will help us understand the stages
involved in production of clinical lesions. Individual or genetic
heterogeneity in cytokine release or response, or in other UVR-
dependent functions, may be a crucial determinant of which patients
develop photosensitive lupus. Although the best evidence for specific
immunologic mechanisms are found in SCLE and NLE, there is promise
that similar specific immunologic mechanisms can be found in ACLE
and CCLE.
Work reported in this paper was supported by grant AR26427 from the National Institutes of
Health and grants from the Dermatology Foundation.
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